Abstracts tagged "Biomarkers"

Abstract Number: 0078 • ACR Convergence 2020
Retrospective Analysis of Clinical Characteristics and Classification Criteria Performance in a Single Center Cohort of 114 Patients Diagnosed with IgG4-Related Disease
Robert Spandorfer¹, Madiha Ahmad² and Arezou Khosroshahi³, ¹Emory University School of Medicine, Atlanta, GA, ²Emory University, Decatur, ³Emory University, Atlanta, GA
Background/Purpose: Immunoglobulin G4 Related Disease (IgG4-RD) is a fibroinflammatory condition that can involve almost any organ system. Diagnosis is made based on correlation of clinical,…
Abstract Number: 0513 • ACR Convergence 2020
Mass Spectrometry Identifies Novel Biomarkers in Giant Cell Arteritis, Useful in Patients on Interleukin-6 Receptor Blockade
Sebastian Unizony¹, Robert Morris², Johannes Kreuzer², Wilhelm Haas² and John H. Stone¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA
Background/Purpose: We aimed to identify biomarkers of disease activity in giant cell arteritis (GCA) patients treated with prednisone monotherapy and with prednisone in combination with…
Abstract Number: 0766 • ACR Convergence 2020
ACPA and Cholesterol Titers as Predictors of Good Clinical Response at One Year in an Argentine Cohort
Rodrigo Garcia Salinas¹, Alvaro Ruta¹, Santiago Ruta¹, Einer Sanchez Prado¹, Jessica Torres Chichande¹ and Sebastian Magri¹, ¹Hospital Italiano La Plata, La Plata, Argentina
Background/Purpose: Autoantibody positivity, erosions, activity level, and functional capacity were classically defined as poor prognosis. Paradoxically, many of them also predict a good response to…
Abstract Number: 1150 • ACR Convergence 2020
Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis
Arianna De Matteis¹, Denise Pires Marafon¹, Ivan Caiello¹, Manuela Pardeo¹, Giulia Marucci¹, Emanuela Sacco¹, Giusi Prencipe¹, Fabrizio De Benedetti² and Claudia Bracaglia¹, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ²Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy
Background/Purpose: Macrophage Activation Syndrome (MAS) and secondary Hemophagocytic Lymphohistiocytosis (sHLH) are hyperinflammatory conditions caused by a cytokine storm, in which IFNγ plays a pivotal role.…
Abstract Number: 1239 • ACR Convergence 2020
Peripheral Protein Biomarker Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Methotrexate Naïve Adults with Moderately-to-Severely Active Rheumatoid Arthritis
Peter Taylor¹, Amer Mirza², Bryan Downie², Jinfeng Liu², Rachael Hawtin² and Emon Elboudwarej², ¹Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Gilead Sciences, Inc., Foster City
Background/Purpose: Filgotinib (FIL), an oral selective JAK1 inhibitor, has shown efficacy and safety in phase 3 studies in adults with moderately-to-severely active rheumatoid arthritis (RA),…
Abstract Number: 1567 • ACR Convergence 2020
Association of Blood Count Biomarkers and Clinical Features with Immune Related Adverse Events (irAEs) in Patients with Cancer Treated with Checkpoint Inhibitors (CPI)
Despina Michailidou¹, Ali R Khaki², Guangyu Wang³, Leonidas Diamantopoulos² and Petros Grivas², ¹Division of Rheumatology, University of Washington, Seattle, Washington, Seattle, WA, ²Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington, Seattle, WA, ³Department of Biostatistics, University of Washington, Seattle, Washington, Seattle, WA
Background/Purpose: Patients with cancer treated with CPI can develop irAEs. Since immune changes may impact blood counts and ratios, we hypothesized that those would be…
Abstract Number: 1809 • ACR Convergence 2020
Serum Cytokine Profiling in Systemic Lupus Erythematosus, Analysed Using Unsupervised Machine Learning, Reveals Clinically Relevant Clusters
Fabien Vincent¹, Jannina Ong¹, Alberta Hoi², Sarah Boyd¹, Hieu Nim¹ and Eric Morand³, ¹Monash University, Clayton, Victoria, Australia, ²Monash University, Melbourne, Victoria, Australia, ³Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: SLE is a heterogeneous disease, where a better understanding of molecular differences between patients is needed in order to direct therapy. Existing approaches generally…
Abstract Number: 2039 • ACR Convergence 2020
Short Telomeres and Autoantibodies Targeting Telomere-Associated Proteins in Scleroderma
Britany Adler¹, Ami Shah², Francesco Boin³, Paul Wolters³, Livia Casciola-Rosen⁴ and Antony Rosen¹, ¹Johns Hopkins University, baltimore, MD, ²Johns Hopkins University School of Medicine, Ellicott City, MD, ³University of California, San Francisco, San Francisco, CA, ⁴Johns Hopkins University, Johns Hopkins University, MD
Background/Purpose: Scleroderma is a systemic fibrosing disease of unknown etiology that often manifests with interstitial lung disease (ILD). Prior studies have found an association between…
Abstract Number: 0171 • ACR Convergence 2020
Interferon Response Gene Expression Differs in Whole Blood, Peripheral Blood Mononuclear Cells, Monocytes, T Cells, B Cells, and NK Cells in Patients with the Autoinflammatory Interferonopathies, CANDLE and SAVI
Jacob Mitchell¹, Sara Alehashemi², Bernadette Marrero³, Yan Huang⁴, Sofia Torreggiani¹, Lena Bichell¹, Gina Montealegre Sanchez⁵, Raphaela Goldbach-Mansky⁶ and Adriana de Jesus⁷, ¹Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, ²Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Clarksville, MD, ³Computational Systems Biology Section/NIAID/NIH, Bethesda, MD, ⁴NIH, Bethesda, ⁵NIAID/NIH, Rockville, MD, ⁶Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD, ⁷Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD
Background/Purpose: The disease progression of patients (pts.) with type-I interferon (IFN)-mediated diseases undergoing treatment with JAK1 and JAK2 inhibitors is monitored in part by measuring…
Abstract Number: 0562 • ACR Convergence 2020
The Relationship Between Heart Disease Risk Profile and Osteoarthritis, Overall and by Multi-/Single-Joint Involvement
Anthony Perruccio¹, Shatabdy Zahid², Calvin Yip³, J Denise Power², Mayilee Canizares², George Heckman⁴ and Elizabeth Badley¹, ¹Krembil Research Institute, UHN; University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴University of Waterloo, Waterloo, ON, Canada
Background/Purpose: Osteoarthritis (OA) and heart disease (HD) are among the most common chronic conditions. Several studies have shown that OA increases the risk of HD…
Abstract Number: 0776 • ACR Convergence 2020
The Influence of Adipokine Profile and Periodontal Infection in Early Stages of Rheumatoid Arthritis and First-degree Relatives
Consuelo Romero-Sanchez¹, Juliette De Avila², Jeimmy Andrea Chaparro-Sanabria³, Philipe Chalem Choueka⁴, Juan Manuel Bello-Gualtero⁵, Alejandro Ramos-Casallas², Lorena Chila-M² and Wilson Bautista-Molano⁶, ¹Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada / Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada /Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, ²Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, ³Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, ⁴Fundacion Instituto de Reumatología Fernando Chalem, Universidad El Rosario, Bogotá D.C., Colombia, ⁵Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada/ Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, ⁶University Hospital Fundación Santa Fé de Bogotá and Universidad El Bosque, Bogotá, Colombia
Background/Purpose: Early RA (eRA) patients have a significant incidence of periodontal inflammation and overweight/obesity. A similar degree of disease activity, functional disability and health-related quality…
Abstract Number: 1151 • ACR Convergence 2020
Implementation and Initial Experience with a Screening Protocol for Inflammatory Hyperferritinemia
Michael Zhang¹, Corinne Schneider², Vinh Dang² and Scott Canna³, ¹Children's Hospital UPMC, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, ³University of PIttsburgh, Pittsburgh, PA
Background/Purpose: Macrophage activation syndrome (MAS) and hemophagocytic lymphohistiocytosis (HLH) epitomize a diverse and deadly group of inflammatory hyperferritinemic syndromes. Early biomarkers distinguishing these syndromes, especially…
Abstract Number: 1240 • ACR Convergence 2020
An Increase in Red Cell Mean Corpuscular Volume by Methotrexate Is Potentiated by Hydroxychloroquine and Predicts Clinical Response in Rheumatoid Arthritis
Muhammad Shipa¹, Su-Ann Yeoh¹, Dev Mukerjee² and Michael Ehrenstein¹, ¹University College London, LONDON, United Kingdom, ²North Middlesex University hospital NHS Trust, London, United Kingdom
Background/Purpose: Methotrexate (MTX) can result in an increase in mean corpuscular volume (MCV) of red blood cells. The range of MCV change varies between patients…
Abstract Number: 1581 • ACR Convergence 2020
Neutrophil to Lymphocyte Ratio as a Predictor of Immune-Related Adverse Events in CTLA-4 Treated Patients: A Retrospective Review
Michael Cunningham¹, Carolina Alvarez², Shruti Saxena Beem³, Todd Schwartz⁴ and Rumey Ishizawar⁵, ¹UNC Hospitals, Durham, NC, ²University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Miami, FL, ³University of North Carolina at Chapel Hill, Chapel Hill, ⁴University of North Carolina-Chapel Hill, Chapel Hill, NC, ⁵University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Immune checkpoint inhibitors (ICIs) target checkpoint proteins PD-1/PD-L1 and CTLA-4 to activate and enhance the cytotoxic effects of T lymphocytes against tumor cells [1-2].…
Abstract Number: 1814 • ACR Convergence 2020
The Association of Urinary Membrane Attack Complex (C5b-9) with Proteinuria and Glomerular Activity in Lupus Nephritis
Shudan Wang¹, Erica Moore², Brianna Lally³, Beatrice Goilav⁴, Chaim Putterman³ and Anna Broder⁵, ¹Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, ³Albert Einstein College of Medicine, Bronx, NY, ⁴The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁵Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
Background/Purpose: Complement activation is known to play a major role in lupus nephritis (LN). Urinary membrane attack complex (C5b-9) has been shown to correlate with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].